Google
KYNB — KYNTRA BIO, INC. (Healthcare >> Biotechnology)
KYNB FAQ
What is KYNB's P/E ratio?
KYNTRA BIO, INC. (KYNB) currently trades at a P/E ratio of 0.19.
What is KYNB's ROE?
KYNTRA BIO, INC. reports a Return on Equity (ROE) of -1,199.70%.
What is KYNB's dividend yield?
KYNTRA BIO, INC. offers a dividend yield of 0.00%.
What is KYNB's Deepscope Quality Score?
Deepscope rates KYNB's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KYNB?
Deepscope's AI Timing Score for KYNB is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KYNB belong to?
KYNTRA BIO, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 6.84
Price
-0.06
(-0.87%)
Day Change
|
|
|---|
KYNB, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROE is relatively low.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
70% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
5
GREAT
|
| Magic Formula Rank by ROE |
5
GREAT
|
| Magic Formula Rank by ROIC |
1
GREAT
|
| Price | 6.84 |
| PBV / Sector |
-3.01 / 4.53
|
| Earning Per Share | 27.29 |
| PE / Sector |
0.19 / 16.80
GREAT
|
| PEG or PE/Growth / Sector |
N/A / 0.51
|
| Average 1M Daily Value |
0.06 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-03 09:11:47 |
| Symbol | KYNB |
| Name | KYNTRA BIO, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.05 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 27.93 / 8,614.17 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 350 Bay Street, San Francisco, CA, United States, 94133
Phone: 415 978 1200
Website: https://www.kyntrabio.com
Sector: Healthcare >> Biotechnology
Description: Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
